INS and metabolic dysfunction-associated steatotic liver disease: For instance, L-carnitine might be an interesting option as adjuvant in people with NAFLD for its role in a number of intracellular and metabolic functions [85]: in preliminary clinical studies, it seems to improve insulin resistance and inflammatory biomarkers, even if data from an RCT of supplementation with 500 mg/twice daily of this molecule for 1 year for the treatment for NAFLD showed no significant changes in liver function tests and ultrasound grade [86].